Dr. David Sidransky

Dr. Sidransky is a renowned oncologist, research scientist and Professor of Oncology and Cellular & Molecular Medicine at John Hopkins University and Hospital. He was among the first researchers to identify p53 mutations and their function in a variety of human cancers. He has published over 600 papers in cancer biology, diagnostics, and therapeutics. Dr. Sidransky was Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for $6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals, (NASDAQ: ONCM), a genetic testing company that was sold to Gene Logic in 1998 and Champions Oncology (NASDAQ: CSBR) a developer of precision models for cancer therapy.